GT BIOPHARMA INC (GTBP)
US36254L3087 - Common Stock
GTBP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. GTBP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GTBP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year GTBP has reported negative net income.
GTBP had a negative operating cash flow in the past year.
In the past 5 years GTBP always reported negative net income.
In the past 5 years GTBP always reported negative operating cash flow.
1.2 Ratios
GTBP has a worse Return On Assets (-97.22%) than 75.44% of its industry peers.
With a Return On Equity value of -181.40%, GTBP is not doing good in the industry: 67.26% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.22% | ||
| ROE | -181.4% | ||
| ROIC | N/A |
ROA(3y)-119.66%
ROA(5y)-2123.63%
ROE(3y)-181.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GTBP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GTBP has more shares outstanding than it did 1 year ago.
GTBP has more shares outstanding than it did 5 years ago.
GTBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
GTBP has an Altman-Z score of -99.42. This is a bad value and indicates that GTBP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GTBP (-99.42) is worse than 97.51% of its industry peers.
GTBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -99.42 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.15 indicates that GTBP has no problem at all paying its short term obligations.
With a Current ratio value of 2.15, GTBP is not doing good in the industry: 74.20% of the companies in the same industry are doing better.
A Quick Ratio of 2.15 indicates that GTBP has no problem at all paying its short term obligations.
GTBP has a worse Quick ratio (2.15) than 72.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.15 | ||
| Quick Ratio | 2.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 53.40% over the past year.
EPS 1Y (TTM)53.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-446.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, GTBP will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.60% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.62%
EPS Next 2Y27.6%
EPS Next 3Y19.48%
EPS Next 5Y12.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GTBP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GTBP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GTBP's earnings are expected to grow with 19.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.6%
EPS Next 3Y19.48%
5. Dividend
5.1 Amount
GTBP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GT BIOPHARMA INC
NASDAQ:GTBP (12/24/2024, 8:18:11 PM)
After market: 3.06 -0.14 (-4.38%)3.2
+0.39 (+13.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners60.11%
Inst Owner Change15.35%
Ins Owners1.8%
Ins Owner Change0%
Market Cap7.14M
Analysts82.86
Price Target11.22 (250.63%)
Short Float %0.56%
Short Ratio0.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.46%
Min EPS beat(2)20.48%
Max EPS beat(2)40.45%
EPS beat(4)4
Avg EPS beat(4)38.27%
Min EPS beat(4)20.48%
Max EPS beat(4)50.98%
EPS beat(8)6
Avg EPS beat(8)24.17%
EPS beat(12)9
Avg EPS beat(12)13.18%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-92.67%
PT rev (3m)-92.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)37.13%
EPS NY rev (3m)37.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.34 | ||
| P/tB | 1.34 | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.13
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-4.53
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS0
BVpS2.38
TBVpS2.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.22% | ||
| ROE | -181.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-119.66%
ROA(5y)-2123.63%
ROE(3y)-181.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.15 | ||
| Quick Ratio | 2.15 | ||
| Altman-Z | -99.42 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-446.67%
EPS Next Y-19.62%
EPS Next 2Y27.6%
EPS Next 3Y19.48%
EPS Next 5Y12.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.01%
OCF growth 3YN/A
OCF growth 5YN/A